Advertisement

Advertisement
Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers

On January 15, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu) for adult patients with...

 

Hepatobiliary Cancer

IDH Inhibitor Ivosidenib Improves Overall Survival in Previously Treated Patients With Cholangiocarcinoma: ClarIDHy Trial

Ivosidenib, an inhibitor of isocitrate dehydrogenase 1 (IDH1), improved overall survival by almost 3 months compared with placebo in previously treated...

 

Hematologic Malignancies
Immunotherapy

FDA Grants Accelerated Approval to Daratumumab Plus Hyaluronidase-fihj for Newly Diagnosed Light Chain Amyloidosis

On January 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to daratumumab plus hyaluronidase-fihj...

 


Advertisement
Colorectal Cancer

Postsurgical Disease Recurrence in Stage I to III Colorectal Cancer May Be Predicted by ctDNA

Patients with stage I to III colorectal cancer and a high risk for disease recurrence may be identified by serial testing of circulating tumor DNA...

 

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement




Leukemia

Curtis Lachowiez, MD, on AML: Venetoclax in Combination With Standard Intensive Induction/Consolidation Therapy

Leukemia

Maintenance Oral Azacitidine for Patients With AML in First Remission: QUAZAR AML-001 Trial

As reported in The New England Journal of Medicine by Andrew H. Wei, MBBS, PhD, and colleagues, the phase III QUAZAR AML-001 trial has shown prolonged overall survival with oral azacitidine maintenance therapy vs placebo in patients with acute myeloid leukemia (AML) in first remission. The oral...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Breast Cancer

Andreas Schneeweiss, MD, on Breast Cancer: Comparing Neoadjuvant Chemotherapy With Paclitaxel, Doxorubicin, and Carboplatin

COVID-19

COA Submits Letter to Governors, Public Health Officials to Request Independent Oncology Practices Be Given Priority Approval to Administer COVID-19 Vaccines

Today, leadership from the Community Oncology Alliance (COA) sent a letter urging the nation's governors and public health officials to prioritize supplying cancer treatment practices with COVID-19 vaccines and allowing the practices to administer the vaccines. The letter, signed by Kashyap Patel,...

Breast Cancer

Palbociclib Plus Endocrine Therapy vs Capecitabine for Patients With HR-Positive, HER2-Negative Breast Cancer: The PEARL Trial

Although patients with hormone receptor (HR)-positive, HER2-negative, aromatase inhibitor–resistant metastatic breast cancer maintained quality of life for a longer time following treatment with palbociclib plus either exemestane or fulvestrant than capecitabine, those receiving chemotherapy...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Leukemia
Lymphoma

David T. Teachey, MD, on Pediatric Leukemia and Lymphoma: New Findings on Cranial Radiation and Bortezomib

Skin Cancer

FDA Pipeline: Two Fast Track Designations for Cavrotolimod in Nonmelanoma Skin Cancers

The U.S. Food and Drug Administration (FDA) has granted two Fast Track designations to cavrotolimod (AST-008). The designations include cavrotolimod in combination with anti–PD-1 therapy for the treatment of patients with locally advanced or metastatic Merkel cell carcinoma refractory to prior...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...